GLP-1 Weight Loss Telehealth in New Jersey

New Jersey is home to roughly 9.3 million people, and about 28.0% of New Jersey adults have obesity. Whether treatment is appropriate for any individual is a licensed physician's decision.

Whether you live in Newark, Jersey City, Paterson or anywhere else in New Jersey, you can start with an online medical assessment once we open, and a physician licensed in New Jersey reviews it and decides whether telehealth treatment is right for you.

New Jersey telehealth rules: New Jersey telehealth practice is governed by N.J.S.A. 45:1-61 and its related sections, which allow a licensed provider to establish a valid provider-patient relationship and prescribe through telemedicine without an initial in-person visit, provided the encounter meets the same standard of care as an office setting.

Start with your questions, not someone else's results. When exploring semaglutide care in New Jersey, prepare what you want to discuss with the clinician: your medical history, current medicines, allergies, previous treatment and practical concerns. Ask what additional information they need to understand your situation and what alternatives they would consider. The first-telehealth-visit guide helps you organize that discussion. A program's general description cannot answer why a particular treatment would be appropriate for you; ask the treating clinician to explain the individual decision and when further assessment may be needed.

Name the product and the professional. Ask which exact medication and formulation is being considered and which pharmacy would dispense it if prescribed. If the discussion includes compounded semaglutide, use this guide to compounded medicines and FDA approval to prepare questions about its status; do not treat a shared ingredient name as a complete product description. This prescription-label guide can help you clarify the product you actually receive with the pharmacist. Get the clinician's full name and credential and check the relevant New Jersey lookup in the verified facts, using the doctor-license guide to compare a physician's record with the name you were given.

Request the complete quote and follow-up plan. Ask which charges cover assessment, medication, supplies, delivery and ongoing visits, and whether any service is optional or billed separately. What changes after an introductory payment, and what happens if no prescription is issued? These questions before paying for a GLP-1 subscription help you request those terms in writing. Before the visit ends, ask how to obtain your summary, contact the treating team and arrange a review of your progress.

New Jersey answers the licensing question twice, once in the statute and once in the Board of Medical Examiners' own rule, and the rule is the blunter of the two.

N.J.S.A. 45:1-62(b) says that any health care provider who uses telemedicine or engages in telehealth while providing care to a patient shall be validly licensed, certified, or registered under Title 45 "to provide such services in the State of New Jersey", shall remain subject to regulation by the appropriate New Jersey State licensing board, shall act in compliance with existing requirements regarding the maintenance of liability insurance, and shall remain subject to New Jersey jurisdiction. The Board then says plainly what that means for physicians. N.J.A.C. 13:35-6B.1(c) requires a Board license from a physician or podiatrist who is "located outside of New Jersey and provides health care services to any patient located in New Jersey by means of telemedicine or telehealth", and, in the same breath, from one located in New Jersey who treats a patient located in or out of the State. The rule creates no separate telemedicine credential: what it requires is a license issued by the Board. The only carve-out in that section, at 13:35-6B.1(d), is narrow: a provider located in another state who consults with a New Jersey licensee but "does not direct patient care" is not treated as providing health care services to a patient in New Jersey. That is a licensure exception. Separately, N.J.S.A. 45:1-63(b) and N.J.A.C. 13:35-6B.4(c) list four further circumstances in which care may be delivered without a proper provider-patient relationship: informal consultations, episodic consultations by an out-of-state specialist at a New Jersey licensee's request, uncompensated assistance in an emergency or disaster, and on-call or cross-coverage service by a designated substitute.

What New Jersey registers separately is the company. Section 45:1-64 provides that each telemedicine or telehealth organization operating in the State "shall annually register with the Department of Health", and shall submit an annual report of de-identified encounter data to the Department. The statutory list is expressly not exhaustive and covers the total number of encounters, the type of technology used, the category of medical condition, the geographic region of the patient and the provider, the patient's age and sex, and any prescriptions issued. The duty runs to the organization, not only to the clinician.

On starting care remotely, the statute is unusually explicit about what it will not permit. Section 45:1-62(i) tells the licensing boards to write telehealth rules, then adds at (i)(2) that in no case shall those rules "require a provider to conduct an initial in-person visit with the patient as a condition of providing services using telemedicine or telehealth". The relationship is built instead out of steps, listed at N.J.S.A. 45:1-63(a) and repeated for physicians at N.J.A.C. 13:35-6B.4: identify the patient by name, date of birth, phone number and address; disclose and validate the clinician's own identity, license, title and specialty; review the patient's medical history and any available records before initiating contact in an initial encounter; determine, as to each unique patient encounter, whether the same standard of care can be met remotely; and, under the rule, give the patient the opportunity to sign a consent form releasing the records of the encounter to a primary care provider. Both lists are written as minimums, not as a closed set. If the standard of care cannot be met remotely, 13:35-6B.3(b) and (c) are direct: the licensee shall not provide the service that way, and "shall advise the patient to obtain services in-person".

Modality is where New Jersey's reputation and New Jersey's rules have drifted apart. The 2017 definition of telemedicine excluded audio-only telephone conversation; P.L.2021, c.310 struck that phrase, so the exclusions in N.J.S.A. 45:1-61 are now only electronic mail, instant messaging, phone text and facsimile transmission. The Board's rule, adopted effective April 20, 2020 with no amendment recorded since, is the stricter document. Its own definition at 13:35-6B.2 still excludes audio-only telephone conversation used in isolation, and 13:35-6B.5(c) requires interactive, real-time, two-way communication technologies including "a video component that allows a licensee to see a patient and the patient to see the licensee". Dropping video is an exception the physician has to earn under 13:35-6B.5(e), and even then the permitted substitute is not a bare phone call: after accessing and reviewing the patient's medical records and concluding that the standard of care can still be met, the licensee may use real-time, two-way audio in combination with asynchronous store-and-forward technology. The looser statutory definition is not the rule a New Jersey physician actually works under.

Prescribing follows from the same logic. N.J.A.C. 13:35-6B.6(a) states that notwithstanding the in-person interaction required elsewhere in the Board's drug rules at N.J.A.C. 13:35-7, a physician working by telemedicine may issue a prescription where doing so is consistent with the standard of care applicable in person. The boundary is at 13:35-6B.6(b): no prescription "based solely on responses provided in an online questionnaire" unless a proper licensee-patient relationship has already been established. The statute at 45:1-62(d)(2) says the same with one added word, barring a prescription based solely on the responses provided in an "online static questionnaire". A hard in-person examination requirement does exist at 45:1-62(e), but it is written for Schedule II controlled dangerous substances, and when the Legislature reopened that subsection in 2026 it reworked the Schedule II carve-outs and left the rest of the section standing.

You can verify any physician's New Jersey license at the New Jersey State Board of Medical Examiners.